Sign inCreate account

Report workspace tools

NCT03521154ACTIVE_NOT_RECRUITINGanonymous

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).

Sponsor

Source record

AstraZeneca

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg

Indication / condition

AI-normalized

Non Small Cell Lung Cancer (Stage III)

Intervention

Source record

Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg

Source & freshness

Source record

NCT ID

NCT03521154

Original source

ClinicalTrials.gov

Source last updated

May 05, 2026

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03521154

Title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).

Sponsor

AstraZeneca

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE3

Condition raw

Non Small Cell Lung Cancer (Stage III)

Condition normalized

Non Small Cell Lung Cancer (Stage III)

Modality raw

non-small cell lung cancer

Modality normalized

small molecule

Target raw

Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg

Target normalized

Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg

Interventions

Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg

Public preview

Source record

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA). is a PHASE3 clinical asset sponsored by AstraZeneca in Non Small Cell Lung Cancer (Stage III). SEO and diligence focus: Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03521154

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE3

Sponsor

AstraZeneca

Executive brief

Investment-Ready Snapshot

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA). is a PHASE3 clinical asset sponsored by AstraZeneca in Non Small Cell Lung Cancer (Stage III). SEO and diligence focus: Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 05, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03521154

Indication

Non Small Cell Lung Cancer (Stage III)

Modality

small molecule

Target

Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg

Intervention

Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.